Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Martin F Kaiser,Andrew Hall,Katrina Walker,Amy Sherborne,Ruth M De Tute,Nicola Newnham,Sadie Roberts,Emma Ingleson, Kristian Bowles,Mamta Garg,Anand Lokare,Christina Messiou,Richard S Houlston,Graham Jackson,Gordon Cook,Guy Pratt,Roger G Owen,Mark T Drayson,Sarah R Brown,Matthew W Jenner

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 7|浏览27

暂无评分

摘要

Our results suggest that Dara-CVRd induction and extended post-ASCT Dara-VRd consolidation markedly improve PFS for UHiR NDMM patients over conventional management, supporting further evaluation of this strategy.

查看译文

关键词

cyclophosphamide,daratumumab,lenalidomide,dexamethasone,bortezomib,ultra-high-risk

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要